Metabolic Disease

  • Indication

    Familial Hypercholesterolemia (FH)

  • Target Gene

    PCSK9

  • Delivery

    In vivo   LNP

Discovery
Lead Optimization
IND Enabling
Clinical Stage
d1_icon003.svg
  • Indication

    ASCVD

  • Target Gene

    Undisclosed

  • Delivery

    In vivo  LNP

Discovery
Lead Optimization
IND Enabling
Clinical Stage
d1_icon003.svg
  • Indication

    Undisclosed

  • Target Gene

    Undisclosed

  • Delivery

    In vivo  LNP

Discovery
Lead Optimization
IND Enabling
Clinical Stage
d1_icon003.svg

Genetic Disease

  • Indication

    Transthyretin Amyloidosis (ATTR)

  • Target Gene

    TTR

  • Delivery

    In vivo  LNP

Discovery
Lead Optimization
IND Enabling
Clinical Stage
d1_icon004.svg
  • Indication

    Alpha-1 Antitrypsin Deficiency (AATD)

  • Target Gene

    Undisclosed

  • Delivery

    In vivo  LNP

Discovery
Lead Optimization
IND Enabling
Clinical Stage
d1_icon004.svg
  • Indication

    Primary Hyperoxaluria (PH1)

  • Target Gene

    HAO1

  • Delivery

    In vivo  LNP

Discovery
Lead Optimization
IND Enabling
Clinical Stage
d1_icon004.svg
  • Indication

    Undisclosed

  • Target Gene

    Undisclosed

  • Delivery

    In vivo  LNP

Discovery
Lead Optimization
IND Enabling
Clinical Stage
d1_icon004.svg
  • Indication

    HAE

  • Target Gene

    Undisclosed

  • Delivery

    In vivo  LNP

Discovery
Lead Optimization
IND Enabling
Clinical Stage
d1_icon004.svg

Infectious Disease

  • Indication

    Hepatitis B

  • Target Gene

    Undisclosed

  • Delivery

    In vivo  LNP

Discovery
Lead Optimization
IND Enabling
Clinical Stage
d1_icon01.svg
  • Indication

    Undisclosed

  • Target Gene

    Undisclosed

  • Delivery

    In vivo  LNP

Discovery
Lead Optimization
IND Enabling
Clinical Stage
d1_icon01.svg